Depressive Disorder
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Will be admitted to this study: who is over 65 years old on the day of the first assessment; in use of antidepressants stable for at least 6 months, diagnosed of major depressive disorder; who is right-handed; and mild to moderate depression, indicating they are resistant to treatment with pharmacological therapy and / or psychotherapy (taken by the Geriatric Depression Scale).
Exclusion criteria
Exclusion criteria: The elderly will not participate in the investigation: using sedatives, anticonvulsants, amantadine or memantine during the study; who has consumed caffeine on the day of stimulation; with a previous history of stroke, epilepsy, traumatic brain injury, unexplained loss of consciousness; in unstable medical conditions; who has metallic objects in the skull, excluding in the mouth, for example, shrapnel; undergoing craniotomy or head injury; who has disease that caused brain damage or neurological disease; using pacemaker (bypass); participating on another concomitant clinical trial; medication change during the study; with Cognitive Impairment (assessed by the Montreal Cognitive Assessment - MoCA, score below 26); diagnosis of Dementia; scores below 10 - because they are not depressed, or above 21 on the Geriatric Depression Scale because there is evidence that ETCC works better in mild to moderate depression (Gálvez et al., 2015).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary aim of the study is evaluate the severity of depression (or remission of symptoms) after 10 sessions of tDCS. Clinical improvement significant will be considered if the reduction of mood severity reaches at least a 25% reduction in the Beck Depression Inventory in the active stimulation group after the 10 sessions compared to the group that received the tDCS sham. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary aims intend to evaluate the impact of the long-term intervention with follow-up evaluations to 3 months, on mood, life satisfaction, sleep quality, pain and executive functions. Clinical improvement significant will be considered if the reduction of this evalues reaches at least a 25% reduction in the active stimulation group after 3 months compared to the group that received the tDCS sham. | — |
Countries
Brazil
Contacts
;